Sangamo Therapeutics, Inc. (SGMO) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -136.28%, forward earnings yield 90.91%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 27/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.0 | -0.04 | 1.58 | 11.10 | - |
| 2017 | -23.5 | 0.75 | 6.82 | 35.02 | - |
| 2018 | -16.3 | 0.00 | 3.04 | 13.18 | - |
| 2019 | -9.9 | 3.45 | 2.17 | 9.16 | - |
| 2020 | -17.3 | -0.54 | 4.21 | 17.75 | - |
| 2021 | -6.1 | -0.17 | 2.89 | 9.79 | - |
| 2022 | -2.5 | -1.55 | 1.64 | 4.35 | - |
| 2023 | -0.4 | -0.02 | 1.14 | 0.54 | - |
| 2024 | -2.1 | 0.03 | 9.04 | 3.56 | - |
| 2025 | -1.0 | 0.09 | -8.25 | 2.98 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.02 | $19.39M | $-71.66M | -369.6% |
| 2017 | $-0.70 | $36.57M | $-54.57M | -149.2% |
| 2018 | $-0.70 | $84.45M | $-68.33M | -80.9% |
| 2019 | $-0.68 | $102.43M | $-75.82M | -74% |
| 2020 | $-0.90 | $118.19M | $-121.12M | -102.5% |
| 2021 | $-1.23 | $110.7M | $-178.3M | -161.1% |
| 2022 | $-1.25 | $111.3M | $-192.28M | -172.8% |
| 2023 | $-1.48 | $176.23M | $-257.83M | -146.3% |
| 2024 | $-0.49 | $57.8M | $-97.94M | -169.4% |
| 2025 | $-0.44 | $39.55M | $-122.93M | -310.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.24 | $-0.37 – $-0.16 | $55.37M | $40.97M – $77.3M | 2 |
| 2027 | $-0.01 | $-0.01 – $-0.01 | $146.31M | $108.27M – $204.26M | 2 |
| 2028 | $0.36 | $0.25 – $0.47 | $269.6M | $266.85M – $272.35M | 2 |
| 2029 | $0.69 | $0.46 – $1.05 | $401.77M | $297.31M – $560.89M | 1 |
| 2030 | $0.76 | $0.51 – $1.16 | $540.07M | $399.66M – $753.96M | 1 |
